在动物和基于细胞的模型中,SA4503通过西格玛-1受体缓解阿德里亚米辛诱导的病
Hideaki Tagashira1, Shinsuke Chida2, Md Shenuarin Bhuiyan3,4
1Department of Integrative Physiology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Akita, Japan.
Pharmaceuticals (Basel, Switzerland)
|February 26, 2025
概括
作为西格玛-1受体 (Sigmar1) 激动剂的SA4503,通过保留Sigmar1-nephrin相互作用来保护脏免受阿德里亚米诱导的损伤. 这表明Sigmar1是球细胞疾病的潜在治疗点.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 西格玛-1受体 (Sigmar1) 是一个细胞内伴侣蛋白,在功能中没有明确的作用.
- 众所周知,阿德里亚米辛 (ADR) 诱导球球膜损伤.
研究的目的:
- 为了研究SA4503的保护作用,选择性Sigmar1激动剂,在阿德里亚米 (ADR) 诱导的球球膜损伤.
- 阐明SA4503的保护作用背后的分子机制.
主要方法:
- 利用体外和体内模型来评估ADR诱导的细胞损伤.
- 评估了细胞存活率,白蛋白透性和尿中的白蛋白水平.
- 研究了Sigmar1-nephrin相互作用,并使用了Sigmar1抗剂 (NE-100) 来确认特异性.
主要成果:
- 西格玛1在细胞和脏组织中高度表达.
- 在小鼠中,SA4503显著降低了ADR诱导的细胞损伤和尿蛋白泄漏.
- SA4503保留了Sigmar1-nephrin相互作用,这种效应被NE-100阻止.
结论:
- 通过SA4503激活Sigmar1,可以防止ADR诱导的细胞损伤和球损伤.
- 稳定Sigmar1-nephrin相互作用是SA4503保护作用的关键机制.
- 西格玛1是包括性综合征在内的球细胞疾病的有前途的治疗标.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
330
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
1.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
01:31Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K